+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Aplastic Anemia - Pipeline Review, H2 2019

  • ID: 4901316
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 107 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • Cellenkos Inc
  • Gamida Cell Ltd
  • Novartis AG
  • MORE
Aplastic Anemia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2019, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • Cellenkos Inc
  • Gamida Cell Ltd
  • Novartis AG
  • MORE
Introduction
Report Coverage
Aplastic Anemia - Overview
Aplastic Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aplastic Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aplastic Anemia - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Advanced Medical Projects
Amgen Inc
ASC Therapeutics Inc
BioLineRx Ltd
Cell Source Inc
Cellenkos Inc
Elixirgen Therapeutics LLC
F. Hoffmann-La Roche Ltd
Gamida Cell Ltd
HemoGenyx LLC
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Regen BioPharma Inc
Aplastic Anemia - Drug Profiles
Aplastic Anemia - Dormant Projects
Aplastic Anemia - Discontinued Products
Aplastic Anemia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Aplastic Anemia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H2 2019
Aplastic Anemia - Pipeline by Advanced Medical Projects, H2 2019
Aplastic Anemia - Pipeline by Amgen Inc, H2 2019
Aplastic Anemia - Pipeline by ASC Therapeutics Inc, H2 2019
Aplastic Anemia - Pipeline by BioLineRx Ltd, H2 2019
Aplastic Anemia - Pipeline by Cell Source Inc, H2 2019
Aplastic Anemia - Pipeline by Cellenkos Inc, H2 2019
Aplastic Anemia - Pipeline by Elixirgen Therapeutics LLC, H2 2019
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Aplastic Anemia - Pipeline by Gamida Cell Ltd, H2 2019
Aplastic Anemia - Pipeline by HemoGenyx LLC, H2 2019
Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Aplastic Anemia - Pipeline by Novartis AG, H2 2019
Aplastic Anemia - Pipeline by Regen BioPharma Inc, H2 2019
Aplastic Anemia - Dormant Projects, H2 2019
Aplastic Anemia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Aplastic Anemia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acceleron Pharma Inc
  • Advanced Medical Projects
  • Amgen Inc
  • ASC Therapeutics Inc
  • BioLineRx Ltd
  • Cell Source Inc
  • Cellenkos Inc
  • Elixirgen Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • HemoGenyx LLC
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Regen BioPharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll